Norris Medicines Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 ,inter alia, to consider and approve As per attachment.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Norris Medicines Ltd (BSE Script Code: 524414) has informed the BSE that a meeting of its Board of Directors is scheduled for Saturday, 14th February 2026 at the company's registered office in Ankleshwar, Gujarat. The main agenda is to consider and approve the Unaudited Financial Results for the quarter ended 31st December 2025 (Q3 FY26), along with the Limited Review Report from the auditors. The notice also mentions that any other business may be taken up with the Chair's permission and majority consent of directors present, including at least one Independent Director. The trading window for dealing in the company's securities has been closed since 1st January 2026 and will reopen 48 hours after the results are declared on the stock exchange.
This is a routine pre-results intimation and does not, by itself, move the stock. Investors should watch the actual Q3 numbers on 14th February 2026 for any surprise on revenue, margins, or profit, since the trading window closure means insiders cannot trade until 48 hours after the announcement.